These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
726 related articles for article (PubMed ID: 30792387)
1. BCL-2 family isoforms in apoptosis and cancer. Warren CFA; Wong-Brown MW; Bowden NA Cell Death Dis; 2019 Feb; 10(3):177. PubMed ID: 30792387 [TBL] [Abstract][Full Text] [Related]
2. In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins. Senft D; Weber A; Saathoff F; Berking C; Heppt MV; Kammerbauer C; Rothenfusser S; Kellner S; Kurgyis Z; Besch R; Häcker G Cell Death Dis; 2015 Nov; 6(11):e1996. PubMed ID: 26610208 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186 [TBL] [Abstract][Full Text] [Related]
4. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFUÂ tumour suppressor. Wu X; Zhang LS; Toombs J; Kuo YC; Piazza JT; Tuladhar R; Barrett Q; Fan CW; Zhang X; Walensky LD; Kool M; Cheng SY; Brekken R; Opferman JT; Green DR; Moldoveanu T; Lum L Nat Cell Biol; 2017 Oct; 19(10):1226-1236. PubMed ID: 28945232 [TBL] [Abstract][Full Text] [Related]
6. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825 [TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392 [TBL] [Abstract][Full Text] [Related]
8. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Chan SL; Yu VC Clin Exp Pharmacol Physiol; 2004 Mar; 31(3):119-28. PubMed ID: 15008953 [TBL] [Abstract][Full Text] [Related]
9. Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Weyhenmeyer B; Murphy AC; Prehn JH; Murphy BM Exp Oncol; 2012 Oct; 34(3):192-9. PubMed ID: 23070004 [TBL] [Abstract][Full Text] [Related]
10. Structural biology of the Bcl-2 family of proteins. Petros AM; Olejniczak ET; Fesik SW Biochim Biophys Acta; 2004 Mar; 1644(2-3):83-94. PubMed ID: 14996493 [TBL] [Abstract][Full Text] [Related]
11. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy. Ramesh P; Medema JP Apoptosis; 2020 Jun; 25(5-6):305-320. PubMed ID: 32335811 [TBL] [Abstract][Full Text] [Related]
12. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472 [TBL] [Abstract][Full Text] [Related]
13. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Peperzak V; Slinger E; Ter Burg J; Eldering E Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871 [TBL] [Abstract][Full Text] [Related]
14. Differential interactions between Beclin 1 and Bcl-2 family members. Erlich S; Mizrachy L; Segev O; Lindenboim L; Zmira O; Adi-Harel S; Hirsch JA; Stein R; Pinkas-Kramarski R Autophagy; 2007; 3(6):561-8. PubMed ID: 17643073 [TBL] [Abstract][Full Text] [Related]
15. Regulation of apoptosis by BH3 domains in a cell-free system. Cosulich SC; Worrall V; Hedge PJ; Green S; Clarke PR Curr Biol; 1997 Dec; 7(12):913-20. PubMed ID: 9382837 [TBL] [Abstract][Full Text] [Related]
16. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511 [TBL] [Abstract][Full Text] [Related]
17. What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy? Brinkmann K; Ng AP; de Graaf CA; Strasser A Cell Death Differ; 2022 Jun; 29(6):1079-1093. PubMed ID: 35388168 [TBL] [Abstract][Full Text] [Related]
18. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174 [TBL] [Abstract][Full Text] [Related]
19. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Zhang J; Huang K; O'Neill KL; Pang X; Luo X Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874 [TBL] [Abstract][Full Text] [Related]
20. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins. Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]